These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
370 related items for PubMed ID: 7630698
41. General immunity reactions after oral administration of inactivated typhoid vaccines in man. Karolcek J, Drăskovicová M, Georch D. Acta Microbiol Acad Sci Hung; 1974; 21(1-2):143-50. PubMed ID: 4440523 [No Abstract] [Full Text] [Related]
43. Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply. Keddy KH, Klugman KP, Robbins JB. Vaccine; 1998; 16(9-10):871-2. PubMed ID: 9682329 [No Abstract] [Full Text] [Related]
44. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. Yang HH, Kilgore PE, Yang LH, Park JK, Pan YF, Kim Y, Lee YJ, Xu ZY, Clemens JD. J Infect Dis; 2001 Jun 15; 183(12):1775-80. PubMed ID: 11372030 [Abstract] [Full Text] [Related]
49. [Study on chimpanzees on the efficacy of an oral typhoid immunization with an inactivated antigen]. Engelhardt H. Ann Sclavo; 1972 Jun 15; 14(5):626-31. PubMed ID: 4205299 [No Abstract] [Full Text] [Related]
50. Typhoid vaccines. Aggarwal A, Dutta AK. Indian J Pediatr; 2001 Aug 15; 68(8):733-6. PubMed ID: 11563251 [Abstract] [Full Text] [Related]
51. Controlled field trial of a typhoid vaccine prepared with a nonmotile mutant of Salmonella typhi Ty2. Wahdan MH, Sippel JE, Mikhail IA, Rahka AE, Anderson ES, Sparks HA, Cvjetanović B. Bull World Health Organ; 1975 Aug 15; 52(1):69-73. PubMed ID: 1082383 [Abstract] [Full Text] [Related]
57. [Emergency prophylaxis of typhoid using the Vi-antigen of typhoid bacteria]. D'iachenko PN, Dzhumaliev ND, Il'in VI, Pavlova TE. Zdravookhr Kirg; 1976 Jul 23; (6):32-5. PubMed ID: 13578 [No Abstract] [Full Text] [Related]
58. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design. Acosta CJ, Galindo CM, Ali M, Elyazeed RA, Ochiai RL, Danovaro-Holliday MC, Page AL, Thiem VD, Jin Y, Park JK, Lee H, Puri MK, Ivanoff B, Agtini MD, Soeharno R, Simanjuntak CH, Punjabi NH, Canh DG, Sur D, Nizami Q, Manna B, Bai-qing D, Anh DD, Honghui Y, Bhattacharya SK, Bhutta Z, Trach DD, Xu ZY, Pang T, Donner A, Clemens JD. Trop Med Int Health; 2005 Dec 23; 10(12):1219-28. PubMed ID: 16359401 [Abstract] [Full Text] [Related]
59. Cellular immunity against Salmonella typhi after live oral vaccine. Nencioni L, Villa L, De Magistris MT, Romano M, Boraschi D, Tagliabue A. Adv Exp Med Biol; 1987 Dec 23; 216B():1669-75. PubMed ID: 3501237 [No Abstract] [Full Text] [Related]
60. Vaccination against intracellular bacterial pathogens. Pang T. Trends Microbiol; 1998 Nov 23; 6(11):433. PubMed ID: 9846359 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]